Clemens A. van Blitterswijk

Polyganics BV engages in the development, manufacture, and commercialization of bioresorbable medical devices that facilitate tissue repair and regeneration. It offers pipeline, peripheral nerve repair, neurosurgery, and general surgery products . The company was founded in 1999 and is headquartered in Groningen, the Netherlands.

Progentix Orthobiology BV develops CuriOs (TM), a unique suite of osteoconductive material products for clinical application in bone regenerative surgery. The company was founded by Joost Dick de Bruijn and Clemens A. van Blitterswijk in 2007 and is headquartered in Bilthoven, the Netherlands.

CellCoTec Ltd. develops surgery cell-based therapy and biomedical products. Its technology which combines cell interaction with the use of a mechanically functional polymer scaffold in a single surgical intervention. The company was founded by Jens Riesle and Jeanine Heendriks in 2004 and is headquartered in London, the United Kingdom.

IsoTis NV manufactures, markets and sells a range of bone graft substitutes and other related medical devices. These devices are used to enhance the repair and regeneration of bone in spinal and trauma surgery, joint replacements and dental applications. IsoTis' products are primarily used spinal fusion, trauma, joint revision, bone void filling and iliac crest backfills procedures. The company is headquartered in Bilthoven, the Netherlands

LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies.

Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland.

EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands.